Obesity management case study
Obesity Management Submitted by Shannon Delite Leake The University of Texas at Arlington College of Nursing In partial fulfillment of the requirements of Advanced Pharmacology N5334 Mary Davis, DNP, MSN, RN, APN-BC, CRNP, ADM-BC November 12, 2017 Benign Prostate Hyperplasia Management 1 Obesity Management CASE SUMMARY: Francine Mallory, a 35-year-old female, complains of fatigue, sleeplessness, hip/knee pain upon physical activity, weepiness, and being overweight. Patient body mass index (BMI) is 31.2. History includes gestational diabetes, insomnia, tension headaches, hemorrhoids, difficulty adjusting post-divorce, with a history of smoking one pack daily for nine years. Family history positive for myocardial infarction, obesity, and diabetes. Plan today is to prescribe Qsymia (phentermine/topiramate), refer to Physical Therapy(PT) for evaluation and treatment if indicated for knee/hip pain, refer to Care Coordinator/Population Health Nurse for health coaching for lifestyle changes, and education of diet and exercise in conjunction with medication treatment for weight loss. 5334 CASE SUMMARY TABLE 1. Symptoms: List two pertinent signs and symptoms Fatigue Knee/hip pain with physical activity Weepiness Sleeplessness BMI 31.2 (Calculate, n.d.). 2. Recommended Drugs: **Drug of choice – list at least 3 recommended drugs List recommended drugs as indicated for this diagnosis Belviq (lorcaserin) (Vallerand, Deglin, & Sanoski, 2017). Qsymia (phentermine/topiramate) (Vallerand, Deglin, Sanoski, 2017). Contrave (naltrexone/bupropion) (Vallerand, Deglin, & Sanoski, 2017). 3. Drug Categories and Subcategories: Identify the category of each recommended drug. 2 Obesity Management Belviq (lorcaserin) is therapeutically a weight control agent, pharmacologically a serotonin 2C receptor agonist, a schedule IV, and a pregnancy category X medication (Vallerand, Deglin, & Sanoski, 2017). Qsymia (phentermine/topiramate) is therapeutically a weight control agent, pharmacologically an appetite suppressant, a schedule IV, and a pregnancy category X medication (Vallerand, Deglin, & Sanoski, 2017). Contrave (naltrexone/bupropion) is therapeutically a weight control agent, pharmacologically an aminoketones, opioid antagonist, and a pregnancy category X medication (Vallerand, Deglin, & Sanoski, 2017). 4. Drug(s) of Choice: FOR THE MAIN DIAGNOSIS ONLY, provide the chosen drug(s) of choice for treatment. 5. Rationale: Provide rationale, clinical guidelines, or evidence for the selected drug of choice Qsymia (phentermine/topiramate) has been approved by the Federal Drug Agency for weight loss based on convincing evidence presented by three clinical trials of weight loss with reduction of comorbidities related to weight (Kim, et al, 2014). 6. Contraindications and or Risks, as appropriate: Identify contraindications and risks as appropriate Qsymia (phentermine/topiramate) hypersensitivity to sympathomimetics, pregnancy, glaucoma, hyperthyroidism, breastfeeding, within two weeks of MAOI use, severe renal and/or hepatic impairment, history of suicidal thought/ideations; use with 3 Obesity Management caution in diabetes, women of childbearing age, history of substance abuse, geriatrics, pediatric patients (Vallerand, Deglin, & Sanoski, 2017). 7. What Patients Must Understand: Identify at least 3 appropriate teaching points for the patient and/or family (HINT: 3 teaching points is rarely adequate for good patient care) Side effects/Adverse reactions include: Seizures upon sudden discontinuation of medication, insomnia, headache, dizziness, mood disorder, cognitive impairment, eye pain, blurred vision, suicidal ideation, acute myopia, tachycardia, acute angle closure glaucoma, altered taste, hypotension, constipation, hepatoxicity, dry mouth, metabolic acidosis, serious skin reactions (StevensJohnson Syndrome, erythema multiforme, toxic epidermal necrolysis), increased creatinine, kidney stones, alopecia, hyperthermia, paresthesia’s, oligohydrosis, decreased sweating, hypokalemia, hypoglycemia. Take this medication as ordered (Vallerand, Deglin, & Sanoski, 2017). Do not take suddenly, this medication must be tapered down (Vallerand, Deglin, Sanoski, 2017). Notify your healthcare professional of any of the side effects/adverse reactions you have been educated on immediately (Vallerand, Deglin, & Sanoskin, 2017). Avoid driving until you know how this medication affects you (Vallerand, Deglin, Sanoski, 2017). Increase your consumption of water to increase your urination to prevent the formation of kidney stones (Vallerand, Deglin, & Sanoski, 2017). Monitor for decreased sweating, especially during exercise and hot weather (Vallerand, Deglin, & Sanoski, 2017). Do not take any over-the-counter medication, herbal supplement, herbal remedy, or any other prescription medication before consulting your healthcare provider (Vallerand, Deglin, & Sanoski, 2017). Notify your healthcare provider if you plan to become, or become pregnant, as this
Document information
- Uploaded on
- November 29, 2021
- Number of pages
- 11
- Written in
- 2021/2022
- Type
- Exam (elaborations)
- Contains
- Questions & answers